We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

A Study of Efavirenz in Combination With Stavudine and Didanosine

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
November 2, 1999
August 31, 2001
December 9, 2005
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
A Study of Efavirenz in Combination With Stavudine and Didanosine
A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Didanosine in Antiretroviral Therapy-Naive HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus didanosine to HIV-infected patients who have never received anti-HIV treatment.
Patients will be given combination treatment with efavirenz, stavudine, and didanosine.
Phase 2
Primary Purpose: Treatment
HIV Infections
  • Drug: Efavirenz
  • Drug: Stavudine
  • Drug: Didanosine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria

Patients must have:

  • Documented HIV infection with plasma HIV-RNA greater than or equal to 10,000 copies/ml.
  • A life expectancy of at least 12 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Current bilateral peripheral neuropathy greater than or equal to Grade 2.
  • Any clinically significant laboratory findings obtained during the screening evaluation (see laboratory values).
  • Any clinically significant disease (other than HIV infection) or clinically significant findings during screening of medical history or physical examination.
  • Any malignancy that requires systemic therapy.
  • Proven or suspected acute hepatitis due to any cause.
  • Recurrent episodes of moderate to severe diarrhea, or vomiting lasting more than 4 days within 3 months prior to dosing.
  • Active AIDS-defining opportunistic infection or disease.

Concurrent Medication:


Astemizole, cisapride, clarithromycin, ketoconazole, itraconazole, midazolam, rifabutin, rifampin, terfenadine, thalidomide, triazolam, vincristine, zalcitabine.

Patients with the following prior conditions are excluded:

  • History of acute or chronic pancreatitis.
  • Life expectancy less than 12 months.
  • Difficulty in swallowing capsules/tablets.
  • Hypersensitivity to any component of the formulation of efavirenz, stavudine, or didanosine.

Prior Medication:


  • Any other experimental drug within 30 days of introducing study treatment.
  • Vaccination within 3 weeks of screening visit.
  • Interferon started within 30 days of initiating study treatment.
  • Prior antiretroviral therapy.

Risk Behavior:


- Current alcohol or illicit drug use which would interfere with compliance with dosing schedule and protocol evaluations.

Sexes Eligible for Study: All
13 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
DMP 266-044
Not Provided
Not Provided
Not Provided
Not Provided
Dupont Merck
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
November 1998

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP